BETA: Please send your feedback!

MacroGenics

NAS:MGNX

Biotechnology

$820.40mm
SMALL cap
$16.50 (-1.84%)
32.7804%
since start of 2019
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 2
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5

About

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. It is focused on three therapeutic areas: Oncology, Autoimmune Disorders and Infectious Diseases. The company's proprietary technology platforms include Dual-Affinity Re-Targeting (DART) Therapeutics, which allow to incorporate multiple specificities within a single molecule; FC Optimization, enhances antibody-dependent functions; and Cancer Stem Cell, which provides a unique discovery tool to identify cancer targets shared by both tumor-initiating cells and differentiated cancer cells. Its infectious disease portfolio includes antibody-based therapeutics for the treatment of infectious diseases from pathogens, such as dengue, smallpox and H5N1. The company's autoimmune program, teplizumab, is an anti-CD3 antibody developed for the prevention and treatment of early onset diabetes. MacroGenics was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
website

Headquarters

9640 Medical Center Drive
Rockville, MD 20850-3368

Executives

Name Title Gender
Leroy E. Hood, MD, PhD Founder Male
Scott E. Koenig, MD, PhD President, Chief Executive Officer & Director Male
Ezio Bonvini, MD Chief Scientific Officer & Senior VP-Research Male
Joseph Panigot Vice President-Legal Affairs Male
Robert Obst, MBA Vice President-Human Resources & Facilities Male
Lynn Cilinski Treasurer, Vice President & Controller Female
Ruedi Aebersold, PhD Founder Male
Alan Aderem, PhD Founder Male
Jeffrey V. Ravetch, MD, PhD Founder Male
Paulo F. Costa, MBA Chairman Male
James Karrels, MBA Chief Financial Officer, Secretary & Senior VP Male
Atul Saran Senior Vice President & General Counsel Male
Jon Wigginton, MD Chief Medical Officer & SVP-Clinical Development Male

Mindful Investing Summary

  • 1
  • 2
  • 3
  • 4
  • 5
  • Carbon Footprint N/A
  • Pollution Prevention N/A
  • Water Conservation N/A
  • Data & Privacy Protection N/A
  • Consumer Health, Wellness & Safety N/A
  • Employee Ownership, Satisfaction, Benefits & Pay N/A
  • Workplace Health and Safety N/A
  • Integrity of Corporate Governance N/A
  • Ethical Practices N/A
  • Usage of Conflict Materials N/A
  • Forced Labor N/A
  • Diversity of Corporate Leadership 2

MacroGenics - Competitors and Related Companies

How MacroGenics stacks up to its peers in the Biotechnology industry or with competing business segments.

MacroGenics

NAS:MGNX

Biotechnology

$820.40mm
SMALL cap
$16.50 (-1.84%)
32.7804%
since start of 2019
  • 2
  • Carbon Footprint
  • Pollution Prevention
  • Water Conservation
  • Data Privacy
  • Consumer Health
  • Employee Satisfaction
  • Workplace Safety
  • Corp Gov
  • Ethical Practices
  • Conflict Materials
  • Forced Labor
  • Gender Diversity
  • 2
  • CF
  • PP
  • WC
  • DP
  • CH
  • ES
  • WS
  • CG
  • EP
  • CM
  • FL
  • GD
  • 1
  • 2
  • 3
  • 4
  • 5
Loading…